SCHEMBL10108616

SCHEMBL10108616

CC(C)N(C)[C@@H](C)[C@@H](O)c1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.70
ALDH1A1 P00352 2/20 0.70
AOC3 Q16853 5/20 0.66
GAA P10253 1/20 0.53
ADRA2C P18825 2/20 0.52
ADRA2A P08913 1/20 0.52
LMNA P02545 1/20 0.52
HIF1A Q16665 1/20 0.52
CHRM2 P08172 1/20 0.48
ADRA1A P35348 1/20 0.48
RGS12 O14924 1/20 0.48
GLA P06280 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
PKM P14618 1/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
ALOX12 P18054 1/20 0.48
NFKB1 P19838 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5962400 1.00 KDM4E (0.70) KDM4EALDH1A1AOC3GAAADRA2C
SCHEMBL13741557 1.00 KDM4E (0.70) KDM4EALDH1A1AOC3GAAADRA2C
SCHEMBL3874299 1.00 KDM4E (0.70) KDM4EALDH1A1AOC3GAAADRA2C
SCHEMBL5962393 1.00 KDM4E (0.70) KDM4EALDH1A1AOC3GAAADRA2C
SCHEMBL12322302 0.85 KDM4E (0.73) KDM4EALDH1A1AOC3GAAADRA2C
SCHEMBL18091009 0.85 KDM4E (0.73) KDM4EALDH1A1AOC3GAAADRA2C
Methylephedrine SCHEMBL99673 0.83 KDM4E (1.00) KDM4EALDH1A1AOC3GAAADRA2C
Methylephedrine SCHEMBL11959977 0.83 KDM4E (1.00) KDM4EALDH1A1AOC3GAAADRA2C
Methylephedrine SCHEMBL2712293 0.83 KDM4E (1.00) KDM4EALDH1A1AOC3GAAADRA2C
Methylephedrine SCHEMBL99674 0.83 KDM4E (1.00) KDM4EALDH1A1AOC3GAAADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101782-B2 Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory COLUCID PHARMACEUTICALS, INC. (US) 2012-01-24 US disclosed
US-20080261950-A1 Compounds that inhibit cholinesterase COLUCID PHARMACEUTICALS, INC. (US) 2008-10-23 US disclosed
US-7345054-B2 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-03-18 US disclosed
US-7304061-B2 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261950-A1 Compounds that inhibit cholinesterase ACHE, BCHE, CHAT KDM4E 1137/4885ALDH1A1 989/4885AOC3 656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.